Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination

Cancer Letters, Год журнала: 2024, Номер 598, С. 217079 - 217079

Опубликована: Июнь 25, 2024

Язык: Английский

---

Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(21), С. 6537 - 6537

Опубликована: Окт. 30, 2024

Next-generation immunotherapies have revolutionized cancer treatment, offering hope for patients with hard-to-treat tumors. This review focuses on the clinical applications and advancements of key immune-based therapies, including immune checkpoint inhibitors, CAR-T cell therapy, new vaccines designed to harness system combat malignancies. A prime example is success pembrolizumab in treatment advanced melanoma, underscoring transformative impact these therapies. Combination treatments, integrating immunotherapy chemotherapy, radiation, targeted are demonstrating synergistic benefits improving patient outcomes. also explores evolving role personalized immunotherapy, guided by biomarkers, genomic data, tumor environment, better target individual Although significant progress has been made, challenges such as resistance, side effects, high costs persist. Technological innovations, nanotechnology artificial intelligence, explored future enablers The evaluates trials, breakthroughs, emerging immune-modulating agents delivery systems that hold great promise enhancing efficacy, reducing toxicity, expanding access immunotherapy. In conclusion, this highlights ongoing reshaping care, strategies poised overcome current further extend therapeutic reach.

Язык: Английский

---

Engineering a Novel T‐Cell Epitope‐Based Vaccine Targeting PRAME in Cancer Immunotherapy

Peptide Science, Год журнала: 2025, Номер 117(1)

Опубликована: Янв. 1, 2025

ABSTRACT PRAME, a cancer/testis antigen, is often expressed abnormally in various cancers, making it hopeful candidate for cancer immunotherapy. This study aimed to create vaccine targeting PRAME using immunoinformatics methods. The protein sequence was obtained from UniProtKB, and TLR4 agonist Mycobacterium tuberculosis included as an adjuvant. Potential T‐cell epitopes were forecasted the IEDB server assessed their antigenicity, lack of allergenicity, binding affinities human murine MHC molecules. Selected then combined into multi‐epitope structure suitable linkers. vaccine's physical chemical properties, 3D structure, interaction with examined through computational analyses. Five promising MHC‐I five MHC‐II pinpointed incorporated displayed advantageous biochemical traits, including high stability, solubility, antigenicity. Molecular docking simulations showcased steady between TLR4, energy −250.5 kcal/mol. dynamics analyses confirmed structural stability minimal distortion vaccine‐TLR4 complex. introduces fresh approach design cancer‐related antigen. exhibits physical, chemical, immunological characteristics, suggesting its potential trigger robust cellular humoral immune responses against PRAME‐positive cancers.

Язык: Английский

---

Recent Advances in Photodynamic Therapy: Metal-Based Nanoparticles as Tools to Improve Cancer Therapy

Pharmaceutics, Год журнала: 2024, Номер 16(7), С. 932 - 932

Опубликована: Июль 12, 2024

Cancer remains a significant global health challenge, with traditional therapies like surgery, chemotherapy, and radiation often accompanied by systemic toxicity damage to healthy tissues. Despite progress in treatment, these approaches have limitations such as non-specific targeting, toxicity, resistance development cancer cells. In recent years, nanotechnology has emerged revolutionary frontier therapy, offering potential solutions challenges. Nanoparticles, due their unique physical chemical properties, can carry therapeutic payloads, navigate biological barriers, selectively target Metal-based nanoparticles, particular, offer properties suitable for various applications. Recent advancements focused on the integration of metal-based nanoparticles enhance efficacy precision photodynamic therapy. Integrating into therapy represents paradigm shift, enabling strategies enhanced specificity reduced off-target effects. This review aims provide comprehensive understanding pivotal role We explore mechanisms, biocompatibility, applications highlighting challenges use, well combining nanoparticles/photodynamic other synergistic approach treatment.

Язык: Английский

---

Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7191 - 7191

Опубликована: Июнь 29, 2024

Hepatocellular carcinoma (HCC) is the most frequent among primary liver tumors (90%) and one of main causes cancer-related death. It develops usually in a chronically inflamed environment, ranging from compensatory parenchymal regeneration to fibrosis cirrhosis: carcinogenesis can potentially happen each these stages. Inflammation determined by chronic viral infection (hepatitis B, hepatitis C, delta viruses) represents an important risk factor for HCC etiology through both direct damage immune-related mechanisms. The deregulation physiological immunological network lead carcinogenesis. recent introduction immunotherapy as gold-standard first-line treatment highlights role immune system inflammation double-edged weapon treatment. In this review we highlight how key hepatocarcinogenesis viral, alcohol metabolic diseases.

Язык: Английский

---

Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development

Drug Discovery Today, Год журнала: 2024, Номер 29(8), С. 104057 - 104057

Опубликована: Июнь 5, 2024

Язык: Английский

---

CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Июль 18, 2024

Immunotherapy has made significant strides in cancer treatment with strategies like checkpoint blockade antibodies and adoptive T cell transfer. Chimeric antigen receptor cells (CAR-T) have emerged as a promising approach to combine these overcome their limitations. This review explores CAR-T living drug for treatment. are genetically engineered immune designed target eliminate tumor by recognizing specific antigens. The study involves comprehensive literature on technology, covering structure optimization, generations, manufacturing processes, gene therapy strategies. It examines haematologic cancers solid tumors, highlighting challenges proposing suicide gene-based mechanism enhance safety. results show advancements particularly optimization generation. process improved broader clinical application. However, series of inherent side effects still need be addressed. In conclusion, hold great promise treatment, but ongoing research is crucial improve efficacy safety oncology patients. proposed offers potential solution mitigate including cytokine release syndrome (the most common toxic effect therapy) the associated neurotoxicity.

Язык: Английский

---

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 9, 2025

Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity known used, they often fail to achieve satisfactory long-term patient outcomes survival. Recently, immunotherapy has shown success patients by harnessing important interactions between immune system cancer. However, many these therapies lead frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, severe cases, fatalities. New approaches like intratumoral immunotherapy, characterized reduced effects, cost, systemic toxicity, offer promising prospects for future applications clinical oncology. In context locally metastatic cancer, combining diverse immunotherapeutic other targeting multiple cancer hallmarks appears crucial. Such combination hold promise improving survival promoting a sustained response. This review aims provide overview approaches, specifically focusing on administration drugs cancers. It also explores integration modalities maximize Additionally, summarizes recent advances discusses novel outlining directions field.

Язык: Английский

---

Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus

Viruses, Год журнала: 2025, Номер 17(4), С. 581 - 581

Опубликована: Апрель 18, 2025

Oncolytic herpes simplex virus (oHSV) represents a promising therapeutic approach to treating cancers by virtue of its selective replication in and lysis tumor cells, with stimulation host antitumor immunity. At present, four OV drugs have been approved for the treatment worldwide, two which are oHSV that received extensive attention, known as T-VEC Delytact. This review discusses history, mechanism action, clinical development, quality control, evaluation principles products, including viral species genetic modifications improved these products’ potential, limitations, future directions. Integration oHSVs immunotherapeutic agents conventional therapies has field malignant tumors. Although much progress achieved, there is still work be done regarding optimization protocols control oncolytic drugs. The approval various underlines their relevance, safety, efficacy, thereby paving way further research aimed at overcoming existing limitations enhancing patient responses.

Язык: Английский

---

Synergistic Enhancement of Chemotherapy-Induced Cell Death and Antitumor Efficacy against Tumoral T-Cell Lymphoblasts by IMMUNEPOTENT CRP

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(14), С. 7938 - 7938

Опубликована: Июль 20, 2024

T-cell malignancies, including acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL), present significant challenges to treatment due their aggressive nature chemoresistance. Chemotherapies remain a mainstay for management, but the aggressiveness of these cancers associated toxicities pose limitations. Immunepotent CRP (ICRP), bovine dialyzable leukocyte extract, has shown promise in inducing cytotoxicity against various cancer types, hematological cancers. In this study, we investigated combined effect ICRP with panel chemotherapies on cell line models T-ALL T-LBL (CEM L5178Y-R cells, respectively) its impact immune system cells (peripheral blood mononuclear splenic bone marrow cells). Our findings demonstrate that combining enhances tumoral lymphoblasts. + Cyclophosphamide (CTX) is induced through caspase-, reactive oxygen species (ROS)-, calcium-dependent mechanism involving loss mitochondrial membrane potential, an increase ROS production, caspase activation. Low doses combination CTX spare non-tumoral overcome marrow-induced resistance death, improves antitumor vivo syngeneic Balb/c mice challenged L5178Y-R. This led reduction tumor volume decrease Ki-67 proliferation marker expression granulocyte/lymphocyte ratio. These results set basis further research into clinical application chemotherapeutic regimens improving outcomes malignancies.

Язык: Английский

---